The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | The benefits and potential of the isatuximab on-body injector in multiple myeloma
In this interview, Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses the benefits and potential of the isatuximab on-body injector (OBI) device in multiple myeloma (MM), highlighting the encouraging safety of this novel mode of administration in clinical trials. The OBI results in a significant reduction in infusion reactions and local reactions compared with intravenous or subcutaneous ‘manual push’ administration, and Prof. Leleu believes that this device could be used at home by patients to reduce the logistical burden and treatment costs. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
